Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial
dc.contributor.author | Kahana, Alon | |
dc.contributor.author | Unsworth, Shelby P. | |
dc.contributor.author | Andrews, Christopher A. | |
dc.contributor.author | Chan, May P. | |
dc.contributor.author | Bresler, Scott C. | |
dc.contributor.author | Bichakjian, Christopher K. | |
dc.contributor.author | Durham, Alison B. | |
dc.contributor.author | Demirci, Hakan | |
dc.contributor.author | Elner, Victor M. | |
dc.contributor.author | Nelson, Christine C. | |
dc.contributor.author | Kim, Denise S. | |
dc.contributor.author | Joseph, Shannon S. | |
dc.contributor.author | Swiecicki, Paul L. | |
dc.contributor.author | Worden, Francis P. | |
dc.date.accessioned | 2021-08-03T18:17:34Z | |
dc.date.available | 2022-08-03 14:17:32 | en |
dc.date.available | 2021-08-03T18:17:34Z | |
dc.date.issued | 2021-07 | |
dc.identifier.citation | Kahana, Alon; Unsworth, Shelby P.; Andrews, Christopher A.; Chan, May P.; Bresler, Scott C.; Bichakjian, Christopher K.; Durham, Alison B.; Demirci, Hakan; Elner, Victor M.; Nelson, Christine C.; Kim, Denise S.; Joseph, Shannon S.; Swiecicki, Paul L.; Worden, Francis P. (2021). "Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial." The Oncologist 26(7): e1240-e1249. | |
dc.identifier.issn | 1083-7159 | |
dc.identifier.issn | 1549-490X | |
dc.identifier.uri | https://hdl.handle.net/2027.42/168524 | |
dc.description.abstract | BackgroundBasal cell carcinoma (BCC) is a common skin cancer often curable by excision; however, for patients with BCC around the eye, excision places visual organs and function at risk. In this article, we test the hypothesis that use of the hedgehog inhibitor vismodegib will improve vision‐related outcomes in patients with orbital and extensive periocular BCC (opBCC).Materials and MethodsIn this open‐label, nonrandomized phase IV trial, we enrolled patients with globe‐ and lacrimal drainage system–threatening opBCC. To assess visual function in the context of invasive periorbital and lacrimal disease, we used a novel Visual Assessment Weighted Score (VAWS) in addition to standard ophthalmic exams. Primary endpoint was VAWS with a score of 21/50 (or greater) considered successful, signifying globe preservation. Tumor response was evaluated using RECIST v1.1. Surgical specimens were examined histologically by dermatopathologists.ResultsIn 34 patients with opBCC, mean VAWS was 44/50 at baseline, 46/50 at 3 months, and 47/50 at 12 months or postsurgery. In total, 100% of patients maintained successful VAWS outcome at study endpoint. Compared with baseline, 3% (95% confidence interval [CI], 0.1–15.3) experienced major score decline (5+ points), 14.7% (95% CI, 5 to 31.1) experienced a minor decline (2–4 points), and 79.4% experienced a stable or improved score (95% CI, 62.1–91.3). A total of 56% (19) of patients demonstrated complete tumor regression by physical examination, and 47% (16) had complete regression by MRI/CT. A total of 79.4% (27) of patients underwent surgery, of which 67% (18) had no histologic evidence of disease, 22% (6) had residual disease with clear margins, and 11% (3) had residual disease extending to margins.ConclusionVismodegib treatment, primary or neoadjuvant, preserves globe and visual function in patients with opBCC. Clinical trail identification number.NCT02436408.Implications for PracticeUse of the antihedgehog inhibitor vismodegib resulted in preservation of end‐organ function, specifically with regard to preservation of the eye and lacrimal apparatus when treating extensive periocular basal cell carcinoma. Vismodegib as a neoadjuvant also maximized clinical benefit while minimizing toxic side effects. This is the first prospective clinical trial to demonstrate efficacy of neoadjuvant antihedgehog therapy for locally advanced periocular basal cell carcinoma, and the first such trial to demonstrate end‐organ preservation.This article reports the results of a prospective clinical trial of vismodegib for patients with basal cell carcinoma occurring in the orbital and periocular regions to assess whether such treatment helps to preserve visual organs and function. | |
dc.publisher | John Wiley & Sons, Inc. | |
dc.subject.other | Visual function | |
dc.subject.other | Epiphora | |
dc.subject.other | Lacrimal | |
dc.subject.other | Cancer | |
dc.subject.other | Tumor | |
dc.subject.other | Orbital | |
dc.subject.other | Orbit | |
dc.subject.other | Hedgehog | |
dc.subject.other | PTCH | |
dc.subject.other | SMO | |
dc.subject.other | Smoothened | |
dc.subject.other | Patched | |
dc.subject.other | Cancer | |
dc.subject.other | Basal cell | |
dc.title | Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Hematology and Oncology | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/168524/1/onco13820-sup-0001-Figures01.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/168524/2/onco13820_am.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/168524/3/onco13820-sup-0002-Tables01.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/168524/4/onco13820.pdf | |
dc.identifier.doi | 10.1002/onco.13820 | |
dc.identifier.source | The Oncologist | |
dc.identifier.citedreference | Smeets NW, Krekels GAM, Ostertag JU et al. Surgical excision vs Mohs’ micrographic surgery for basal‐cell carcinoma of the face: Randomised controlled trial. Lancet 2004; 364: 1766 – 1772. | |
dc.identifier.citedreference | Rogers HW, Weinstock MA, Feldman SR et al. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol 2015; 151: 1081 – 1086. | |
dc.identifier.citedreference | Ye J, Lou L, Jin K et al. Vision‐related quality of life and appearance concerns are associated with anxiety and depression after eye enucleation: A cross‐sectional study. PLoS One 2015; 10: e0136460. | |
dc.identifier.citedreference | Rasmussen ML, Ekholm O, Prause JU et al. Quality of life of eye amputated patients. Acta Ophthalmol 2012; 90: 435 – 440. | |
dc.identifier.citedreference | Eberl M, Mangelberger D, Swanson JB et al. Tumor architecture and Notch signaling modulate drug response in basal cell carcinoma. Cancer Cell 2018; 33: 229 – 243.e4. | |
dc.identifier.citedreference | Nan H, Kraft P, Hunter DJ et al. Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians. Int J Cancer 2009; 125: 909 – 917. | |
dc.identifier.citedreference | Furdova A, Lukacko P. Periocular basal cell carcinoma predictors for recurrence and infiltration of the orbit. J Craniofac Surg 2017; 28: e84 – e87. | |
dc.identifier.citedreference | Leibovitch I, McNab A, Sullivan T et al. Orbital invasion by periocular basal cell carcinoma. Ophthalmology 2005; 112: 717 – 723. | |
dc.identifier.citedreference | Howard GR, Nerad JA, Carter KD et al. Clinical characteristics associated with orbital invasion of cutaneous basal cell and squamous cell tumors of the eyelid. Am J Ophthalmol 1992; 113: 123 – 133. | |
dc.identifier.citedreference | Weesie F, Naus NC, Vasilic D et al. Recurrence of periocular basal cell carcinoma and squamous cell carcinoma after Mohs micrographic surgery: A retrospective cohort study. Br J Dermatol 2019; 180: 1176 – 1182. | |
dc.identifier.citedreference | Saleh GM, Desai P, O Collin JR et al. Incidence of eyelid basal cell carcinoma in England: 2000‐2010. Br J Ophthalmol 2017; 101: 209 – 212. | |
dc.identifier.citedreference | Gerring RC, Ott CT, Curry JM et al. Orbital exenteration for advanced periorbital non‐melanoma skin cancer: Prognostic factors and survival. Eye (Lond) 2017; 31: 379 – 388. | |
dc.identifier.citedreference | Hoban PR, Ramachandran S, Strange RC. Environment, phenotype and genetics: Risk factors associated with BCC of the skin. Expert Rev Anticancer Ther 2002; 2: 570 – 579. | |
dc.identifier.citedreference | Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228 – 247. | |
dc.identifier.citedreference | Ben Ishai M, Tiosano A, Fenig E et al. Outcomes of vismodegib for periocular locally advanced basal cell carcinoma from an open‐label trial. JAMA Ophthalmol 2020; 138: 749 – 755. | |
dc.identifier.citedreference | Gill HS, Moscato EE, Chang ALC et al. Vismodegib for periocular and orbital basal cell carcinoma. JAMA Ophthalmol 2013; 131: 1591 – 1594. | |
dc.identifier.citedreference | Sagiv O, Nagarajan P, Ferrarotto R et al. Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma. Br J Ophthalmol 2019; 103: 775 – 780. | |
dc.identifier.citedreference | Eiger‐Moscovich M, Reich E, Tauber G et al. Efficacy of vismodegib for the treatment of orbital and advanced periocular basal cell carcinoma. Am J Ophthalmol 2019; 207: 62 – 70. | |
dc.identifier.citedreference | González AR, Etchichury D, Gill ME et al. Neoadjuvant Vismodegib and mohs micrographic surgery for locally advanced periocular basal cell carcinoma. Ophthalmic Plast Reconstr Surg 2019; 35: 56 – 61. | |
dc.identifier.citedreference | Kahana A, Worden FP, Elner VM. Vismodegib as eye‐sparing adjuvant treatment for orbital basal cell carcinoma. JAMA Ophthalmol 2013; 131: 1364 – 136. | |
dc.identifier.citedreference | Sofen H, Gross KG, Goldberg LH et al. A phase II, multicenter, open‐label, 3‐cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol 2015; 73: 99 – 105.e1. | |
dc.identifier.citedreference | Kwon GP, Ally MS, Bailey‐Healy I et al. Update to an open‐label clinical trial of vismodegib as neoadjuvant before surgery for high‐risk basal cell carcinoma (BCC). J Am Acad Dermatol 2016; 75: 213 – 215. | |
dc.identifier.citedreference | Ally MS, Aasi S, Wysong A et al. An investigator‐initiated open‐label clinical trial of vismodegib as a neoadjuvant to surgery for high‐risk basal cell carcinoma. J Am Acad Dermatol 2014; 71: 904 – 911.e1. | |
dc.identifier.citedreference | LoRusso, PM, Rudin CM, Reddy JC et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC‐0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011; 17: 2502 – 2511. | |
dc.identifier.citedreference | Tang JY, Mackay‐Wiggan JM, Aszterbaum M et al. Inhibiting the hedgehog pathway in patients with the basal‐cell nevus syndrome. N Engl J Med 2012; 366: 2180 – 2188. | |
dc.identifier.citedreference | Von Hoff DD, LoRusso PM, Rudin CM et al. Inhibition of the hedgehog pathway in advanced basal‐cell carcinoma. N Engl J Med 2009; 361: 1164 – 1172. | |
dc.identifier.citedreference | Sekulic A, Migden MR, Oro AE et al. Efficacy and safety of vismodegib in advanced basal‐cell carcinoma. N Engl J Med 2012; 366: 2171 – 2179. | |
dc.identifier.citedreference | Axelson M, Liu K, Jiang X et al. U.S. Food and Drug Administration approval: Vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin Cancer Res 2013; 19: 2289 – 2293. | |
dc.identifier.citedreference | Xie J, Murone M, Luoh SM et al. Activating Smoothened mutations in sporadic basal‐cell carcinoma. Nature 1998; 391: 90 – 92. | |
dc.identifier.citedreference | Johnson RL, Rothman AL, Xie J et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996 272: 1668 – 1671. | |
dc.identifier.citedreference | Shi Y, Jia R, Fan X. Ocular basal cell carcinoma: A brief literature review of clinical diagnosis and treatment. Onco Targets Ther 2017; 10: 2483 – 2489. | |
dc.identifier.citedreference | Sun MT, Wu A, Figuiera E et al. Management of periorbital basal cell carcinoma with orbital invasion. Future Oncol 2015; 11: 3003 – 3010. | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.